PCSK9 Inhibitors (e.g., Evolocumab, Alirocumab)

Type: drug

Status: FDA Approved

Developer: Amgen (Evolocumab), Sanofi/Regeneron (Alirocumab)

Breakthrough Summary

No summary available.

Mechanism of Action

Details pending.

Year: 2026